DelveInsight’s, “Neurofibromatosis Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 17+ pipeline drugs in the Neurofibromatosis pipeline landscape. It covers the Neurofibromatosis pipeline drug profiles, including Neurofibromatosis clinical trials and nonclinical stage products. It also covers the Neurofibromatosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Neurofibromatosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Neurofibromatosis clinical trials studies, Neurofibromatosis NDA approvals (if any), and product development activities comprising the technology, Neurofibromatosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Neurofibromatosis Pipeline treatment landscape of the report, click here @ Neurofibromatosis Pipeline Outlook

 

Key Takeaways from the Neurofibromatosis Pipeline Report

• DelveInsight’s Neurofibromatosis Pipeline analysis depicts a robust space with 15+ active players working to develop 17+ pipeline treatment therapies.
• The leading Neurofibromatosis Companies are working in the market include NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Array BioPharma, Recursion Pharmaceuticals, Zhejiang Betta Pharma, Healx, INTiDYN, Takeda, Chia Tai Tianqing Pharmaceutical Group, Novartis, AstraZeneca, Merck Sharp & Dohme LLC, Shanghai Kechow Pharma Inc, and others.
• Emerging Neurofibromatosis Pipeline Therapies in the various stages of development include AL2846 capsules, Selumetinib, HL-085, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, NFX-179 gel, and others
• On May 2023, Shanghai Kechow Pharma has announced drug named HL-085 by the phase 2. This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN). The study includes 2 parts, phase IIa and IIb. Phase IIa is to evaluate the preliminary safety, pharmacokinetic characteristics and efficacy of HL-085, and to determine the recommended dose.  
• On April 2023, AstraZeneca has announced drug named Selumetinib granule formulation by the phase 1 & 2. This study is designed to define a dosing regimen and assess the pharmacokinetics (PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 years with NF1 related symptomatic, inoperable PN.

 

Neurofibromatosis Overview

Neurofibromatosis (NF) is one of the most common genetic disorders. Inherited in an autosomal dominant fashion, this phacomatosis is classified into two genetically distinct subtypes characterized by multiple cutaneous lesions and tumors of the peripheral and central nervous system.

 

For further information, refer to the detailed Neurofibromatosis Unmet Needs, Neurofibromatosis Market Drivers, and Market Barriers, click here for Neurofibromatosis Ongoing Clinical Trial Analysis

 

Neurofibromatosis Emerging Drugs Profile

• NFX-179: NFlection Therapeutics
• Mirdametinib: SpringWorks Therapeutics
• Brigatinib: Takeda

 

Neurofibromatosis Pipeline Therapeutics Assessment

There are approx. 15+ Neurofibromatosis companies which are developing the therapies for Neurofibromatosis. The Neurofibromatosis companies which have their Neurofibromatosis drug candidates in the most advanced stage, i.e. phase II include, NFlection Therapeutics.

 

Request a sample and discover the recent advances in Neurofibromatosis Ongoing Clinical Trial Analysis and Medications, click here @ Neurofibromatosis Treatment Landscape

 

Neurofibromatosis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Neurofibromatosis Therapeutics Market include-

NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Array BioPharma, Recursion Pharmaceuticals, Zhejiang Betta Pharma, Healx, INTiDYN, Takeda, Chia Tai Tianqing Pharmaceutical Group, Novartis, AstraZeneca, Merck Sharp & Dohme LLC, Shanghai Kechow Pharma Inc, and others.

 

Dive deep into rich insights for drugs for Neurofibromatosis Pipeline, click here @ Neurofibromatosis Unmet Needs and Analyst Views

 

Scope of the Neurofibromatosis Pipeline Report

• Coverage- Global
• Neurofibromatosis Companies- NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Array BioPharma, Recursion Pharmaceuticals, Zhejiang Betta Pharma, Healx, INTiDYN, Takeda, Chia Tai Tianqing Pharmaceutical Group, Novartis, AstraZeneca, Merck Sharp & Dohme LLC, Shanghai Kechow Pharma Inc, and others.
• Neurofibromatosis Therapies- AL2846 capsules, Selumetinib, HL-085, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, NFX-179 gel, and others.
• Neurofibromatosis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neurofibromatosis Merger and acquisitions, Neurofibromatosis Licensing Activities @ Neurofibromatosis Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Neurofibromatosis Executive Summary
3. Neurofibromatosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neurofibromatosis – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. NFX-179: NFlection Therapeutics
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. REC 2282: Recursion Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Neurofibromatosis Key Companies
15. Neurofibromatosis Key Products
16. Neurofibromatosis- Unmet Needs
17. Neurofibromatosis- Market Drivers and Barriers
18. Neurofibromatosis- Future Perspectives and Conclusion
19. Neurofibromatosis Analyst Views
20. Neurofibromatosis Key Companies
21. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit